| Cambridge Heart's MTWA Test Featured as Case of the Week in Diagnostic and Interventional Cardiology |
|
MTWA Warns of Impending Cardiac Arrest TEWKSBURY, Mass., Sep 29, 2011 -- Cambridge Heart, Inc. (OTCBB: CAMH), a developer of non-invasive diagnostic tests for cardiac disease, today announced that a case study recently featured in Diagnostic and Interventional Cardiology (DAIC) as the Case of the Week highlights Cambridge Heart's Microvolt T-Wave AlternansTM (MTWA) test. The clinical case illustrates a patient who experienced sudden cardiac arrest (SCA) during the recovery portion of an exercise stress test. While there were no symptoms or visible abnormalities on the ECG that would alert the physician to the impending life-threatening event, Cambridge Heart's HearTwave II system detected significant levels of MTWA immediately prior to the cardiac arrest. The patient was successfully resuscitated and subsequently underwent coronary bypass surgery. "This case suggests that MTWA may indicate the presence of active ischemia that is particularly arrhythmogenic and may identify patients in whom coronary angiography should not be delayed," noted Dr. Parag V. Patel, interventional cardiologist and CRM device specialist at Advocate Lutheran General Hospital, Park Ridge, Illinois, and the author of this case. "As such, MTWA may be used to enhance the diagnostic yield of traditional stress testing." "This dramatic case illustrates how MTWA complements existing stress testing protocols by providing unique clinical information about a patient's risk for potentially life-threatening heart rhythms," says Dr. Ali Haghighi-Mood, CEO of Cambridge Heart. "Stories like this are a stark reminder that prediction and prevention are critical to stemming the SCA epidemic that claims 300,000 lives each year." The case study can be found on the DAIC website at: http://www.dicardiology.com/article/mtwa-warns-impending-cardiac-arrest Diagnostic & Interventional Cardiology is the widest-reaching provider of new product information, technology trends, application strategies and related connectivity solutions in the diagnostic and interventional cardiology markets. Sudden Cardiac Arrest (SCA) is the leading cause of death in the U.S. accounting for an estimated 300,000 deaths each year - more than lung cancer, breast cancer and HIV/AIDS combined. Out-of-hospital survival is less than 8 percent, making prediction and prevention critically important. It is estimated that there are approximately 10 to 12 million heart attack and heart failure patients in the U.S. who can benefit from annual MTWA testing. Microvolt T-Wave Alternans is a marker of SCA risk which is measured during a non-invasive treadmill test using Cambridge Heart's proprietary technologies. The Company's MTWA test is the only one of its kind that is reimbursed by Medicare under a National Coverage Policy. About Cambridge Heart, Inc. Cambridge Heart develops and commercializes non-invasive diagnostic tests for cardiac disease, with a focus on identifying those at risk for sudden cardiac arrest (SCA). The Company's products incorporate proprietary Microvolt T-Wave Alternans measurement technologies, including the patented Analytic Spectral Method(R) and ultrasensitive disposable electrode sensors. The Company's MTWA test, originally based on research conducted at the Massachusetts Institute of Technology, is reimbursed by Medicare under its National Coverage Policy. Cambridge Heart, founded in 1990, is based in Tewksbury, MA. It is traded on the Over-The-Counter Bulletin Board (OTCBB) under the symbol CAMH.OB. Statements contained in this press release that are not purely historical are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995.In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates", "could", and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements.Actual results may differ materially from those indicated by these forward-looking statements.Factors that may cause or contribute to such differences are identified in our most recent Annual Report on Form 10-K under "Risk Factors", which is on file with the SEC and available at www.EDGAR.com.In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date.While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so except as may be legally necessary, even if our estimates should change. SOURCE: Cambridge Heart, Inc. At Cambridge Heart: |
